메뉴 건너뛰기




Volumn 99, Issue 6, 2014, Pages 2086-2094

Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; LENVATINIB; PAZOPANIB; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; VEMURAFENIB;

EID: 84902334839     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3588     Document Type: Article
Times cited : (82)

References (24)
  • 2
    • 0042166011 scopus 로고    scopus 로고
    • Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma
    • Shoup M, Stojadinovic A, Nissan A, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg. 2003;197:191-197.
    • (2003) J Am Coll Surg , vol.197 , pp. 191-197
    • Shoup, M.1    Stojadinovic, A.2    Nissan, A.3
  • 3
    • 33747642244 scopus 로고    scopus 로고
    • Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy
    • Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899.
    • (2006) J Clin Endocrinol Metab , vol.91 , pp. 2892-2899
    • Durante, C.1    Haddy, N.2    Baudin, E.3
  • 5
    • 84875305916 scopus 로고    scopus 로고
    • Optimizing therapy for radioactive iodinerefractory differentiated thyroid cancer: Current state of the art and future directions
    • Dadu R, Cabanillas ME. Optimizing therapy for radioactive iodinerefractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol. 2012;37:335-356.
    • (2012) Minerva Endocrinol , vol.37 , pp. 335-356
    • Dadu, R.1    Cabanillas, M.E.2
  • 6
    • 63849265332 scopus 로고    scopus 로고
    • Phase II trial of sorafenib in metastatic thyroid cancer
    • Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-1684.
    • (2009) J Clin Oncol , vol.27 , pp. 1675-1684
    • Kloos, R.T.1    Ringel, M.D.2    Knopp, M.V.3
  • 7
    • 50649095250 scopus 로고    scopus 로고
    • Phase II trial of sorafenib in advanced thyroid cancer
    • Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714-4719.
    • (2008) J Clin Oncol , vol.26 , pp. 4714-4719
    • Gupta-Abramson, V.1    Troxel, A.B.2    Nellore, A.3
  • 8
    • 72949106263 scopus 로고    scopus 로고
    • Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differe ntiated thyroid carcinoma
    • Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differe ntiated thyroid carcinoma. Eur J Endocrinol. 2009;161:923-931.
    • (2009) Eur J Endocrinol , vol.161 , pp. 923-931
    • Hoftijzer, H.1    Heemstra, K.A.2    Morreau, H.3
  • 9
    • 84867527699 scopus 로고    scopus 로고
    • Long term analysis of the efficacy and tolerabi lity of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: Final results of a phase II trial
    • Schneider T, Abdulrahman R, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long term analysis of the efficacy and tolerabi lity of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol. 2012; 167:643-650.
    • (2012) Eur J Endocrinol , vol.167 , pp. 643-650
    • Schneider, T.1    Abdulrahman, R.2    Corssmit, E.P.3    Morreau, H.4    Smit, J.W.5    Kapiteijn, E.6
  • 10
    • 79960179069 scopus 로고    scopus 로고
    • Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population
    • Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol. 2011;165:315-322.
    • (2011) Eur J Endocrinol , vol.165 , pp. 315-322
    • Ahmed, M.1    Barbachano, Y.2    Riddell, A.3
  • 11
    • 84887111477 scopus 로고    scopus 로고
    • Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial
    • abstract 4
    • Brose M, Nuyying C, Jarzab B, et al . Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol. 2013;31:abstract 4.
    • (2013) J Clin Oncol , vol.31
    • Brose, M.1    Nuyying, C.2    Jarzab, B.3
  • 12
    • 62849099971 scopus 로고    scopus 로고
    • Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib
    • Zimmermann K, Schm ittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology. 2009;76:350-354.
    • (2009) Oncology , vol.76 , pp. 350-354
    • Zimmermann, K.1    Schm Ittel, A.2    Steiner, U.3
  • 13
    • 58949092548 scopus 로고    scopus 로고
    • Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
    • Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61-67.
    • (2009) Cancer , vol.115 , pp. 61-67
    • Dudek, A.Z.1    Zolnierek, J.2    Dham, A.3    Lindgren, B.R.4    Szczylik, C.5
  • 14
    • 79959782949 scopus 로고    scopus 로고
    • Sequenti al use of sorafenib and sunitinib in advanced renal-cell carcinoma (rcc): An Italian multicentre retrospective analysis of 189 patient cases
    • Porta C, Procopio G, Carteni G, et al. Sequenti al use of sorafenib and sunitinib in advanced renal-cell carcinoma (rcc): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011; 108:E250-E257.
    • (2011) BJU Int , vol.108
    • Porta, C.1    Procopio, G.2    Carteni, G.3
  • 16
    • 67349163859 scopus 로고    scopus 로고
    • Sequential sorafenib and sunitinib for renal cell carcinoma
    • Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29-34.
    • (2009) J Urol , vol.182 , pp. 29-34
    • Sablin, M.P.1    Negrier, S.2    Ravaud, A.3
  • 17
    • 84875151746 scopus 로고    scopus 로고
    • Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC
    • abstract 5547
    • Cabanillas ME, Brose M, Lee Y, Mile s D, Sherman SI. Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC). J Clin Oncol Vol. 2012;30: abstract 5547.
    • J Clin Oncol , vol.2012 , pp. 30
    • Cabanillas, M.E.1    Brose, M.2    Lee, Y.3    Mile, S.D.4    Sherman, S.I.5
  • 18
    • 78049462514 scopus 로고    scopus 로고
    • Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation
    • Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010; 16:5260-5268.
    • (2010) Clin Cancer Res , vol.16 , pp. 5260-5268
    • Carr, L.L.1    Mankoff, D.A.2    Goulart, B.H.3
  • 19
    • 77954476036 scopus 로고    scopus 로고
    • Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M. D. Anderson experience
    • Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin End ocrinol Metab. 2010;95:2588-2595.
    • (2010) J Clin End Ocrinol Metab , vol.95 , pp. 2588-2595
    • Cabanillas, M.E.1    Waguespack, S.G.2    Bronstein, Y.3
  • 20
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 21
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1
    • Eisenhauer EA Therasse P Bogaerts J et al New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1 Eur J Cancer. 2009 45 228-247.
    • (2009) Eur J Cancer , vol.45 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3
  • 22
    • 77957359933 scopus 로고    scopus 로고
    • Efficacy of pazopanib in progressive, radioio dine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study
    • Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioio dine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010;11:962-972.
    • (2010) Lancet Oncol , vol.11 , pp. 962-972
    • Bible, K.C.1    Suman, V.J.2    Molina, J.R.3
  • 23
    • 84865552505 scopus 로고    scopus 로고
    • Vandetanib in loc ally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial
    • Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in loc ally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13:897-905.
    • (2012) Lancet Oncol , vol.13 , pp. 897-905
    • Leboulleux, S.1    Bastholt, L.2    Krause, T.3
  • 24
    • 80053160399 scopus 로고    scopus 로고
    • A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC
    • Abstract 5503
    • Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011; 29:Abstract 5503.
    • (2011) J Clin Oncol , vol.29
    • Sherman, S.I.1    Jarzab, B.2    Cabanillas, M.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.